Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 +1.27%75 3-Year EBITDA Growth Rate is 149.90% as of Jun. 2026, which is 22% above its 10-year median of 122.50. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.89 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Mentice AB ranks better than 99.13% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 149.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mentice AB was 149.90% per year. The lowest was -55.90% per year. And the median was 122.50% per year.
Mentice AB (FRA:MN2) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Mentice AB 3-Year EBITDA Growth Rate Related Terms
FRA:MN2 vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Mentice AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Mentice AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 149.90% mean?
Mentice AB (FRA:MN2) has a 3-Year EBITDA Growth Rate of 149.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mentice AB and its competitors. This is 22% above median its historical median of 122.50. According to the industry distribution chart, Mentice AB ranks #6 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 0.90000000000001%.
Is Mentice AB's 3-Year EBITDA Growth Rate too high?
Mentice AB's current 3-Year EBITDA Growth Rate of 149.90% is 22% above median its 10-year median of 122.50. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Mentice AB's value of 149.90% is 1846.8% above this industry median. Based on the distribution chart, Mentice AB ranks #6 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #6 out of 691 companies for 3-Year EBITDA Growth Rate. This places Mentice AB in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.70. Mentice AB's value of 149.90% is 1846.8% above this benchmark. While the company's 10-year median is 122.50 vs. the industry median of 7.70, Mentice AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current 3-Year EBITDA Growth Rate of 149.90% is 1846.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current 3-Year EBITDA Growth Rate is 149.90%, which is 22% above median its own 10-year median of 122.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.89, compared to a current price of €1.20 — trading 36.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 149.90%, which is 22% above median its 10-year median of 122.50 and 1846.8% above the Medical Devices & Instruments industry median of 7.70. Mentice AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current 3-Year EBITDA Growth Rate is 149.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.20 is trading 36.8% below its estimated GF Value™ of €1.89.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
3-Year EBITDA Growth Rate: 149.90% (22% above median its 10-year median of 122.50)
GF Value™: €1.89 vs. price of €1.20 (36.8% below fair value)
Industry Position: 1846.8% above the Medical Devices & Instruments median (#6 of 691)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
